On the recordJuly 27, 2022
The FDA needs to provide regulatory pathways for products containing CBD. The FDA needs to act now.
Said by
Ryan F. Quarles
Source
congress.govThe FDA needs to provide regulatory pathways for products containing CBD. The FDA needs to act now.
Quarles emphasizes the urgency for FDA guidance on CBD products to stimulate investment.
Share
More from Ryan F. Quarles
It is not our intention. Indeed, it is the opposite of our intention, to affect the total loss-absorbing capacity of the largest firms.
Kentucky's legislative and regulatory framework is widely recognized today as one of the best in the nation.
If there is a credit allocation decision to be made, that is a decision for Congress, to be debated by the public's representatives.
We feel strongly that hemp is a commodity crop. It is legal to produce and that we should not be criminalizing or intending to criminalize producers for producing a legal crop.